Business Wire

YOKOGAWA-ELECTRIC

Share
Yokogawa Releases Dynamic Real Time Optimizer, a New Solution in the OpreX Asset Operations and Optimization Family

Yokogawa Electric Corporation (TOKYO:6841) announces the release of Dynamic Real Time Optimizer, a solution in the OpreXTM Asset Operations and Optimization family. Using a combination of first principles simulation and multivariable predictive control technology, the Dynamic Real Time Optimizer software helps to optimize plant operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005009/en/

This integrated solution is based on Yokogawa’s advanced process control technologies and industry knowledge and simulation technologies developed by KBC Advanced Technologies Limited (KBC, CEO: Andrew Howell), a UK-based Yokogawa subsidiary. This solution enables plants to quickly respond to dynamically changing oil market and product market conditions and improve both productivity and profitability.

Development Background

Advanced process control systems improve product yield and reduce energy consumption by maintaining temperature, flow rate, pressure, and other process variables within a set range and keeping them as close as possible to their optimal values, even for production processes whose parameters are not easily controlled by conventional control systems. Such advanced control systems are increasingly used in facilities such as oil refineries, petrochemical plants, chemical plants, and natural gas liquefaction trains. Advanced control solutions are attracting considerable interest due to their high economic value.

Multivariable advanced control systems determine the optimal value for plant independent variables. The optimal values are calculated based on information such as feedstock quality and prices, product specifications and prices, and energy costs. In a dynamically changing market, an advanced control system optimizes the operation of a plant in real time based on changes in raw material properties, product demand, and operating conditions.

Using our advanced control technology and KBC’s industry knowledge and simulation technology, we are able to perform highly accurate dynamic real-time optimization using rigorous models, in response to dynamically changing plant and market conditions.

Features

Dynamic Real Time Optimizer calculates the optimal values for plant independent variables with a high level of accuracy and was developed based on KBC’s Petro-SIMTM process simulation platform, which includes functions for online use. This solution acquires data through online connections to control systems and plant information management systems (PIMSs) and carries out case study simulations to generate rigorous models and calculate additional inferred properties. Based on these models and operating conditions, the optimal values are calculated by applying mathematical programming*1 , and implemented online by the advanced control system.

1. Multi-unit optimization based on simulations performed using rigorous models

With large-scale applications, advanced control systems need to be able to quickly process huge amounts of data. Advanced control and optimization systems must have the processing speed needed to calculate the optimal values for such large applications. However, commercially-available products today are only suitable for small- to medium-size applications and can only optimize the control of individual process units. Yokogawa’s Platform for Advanced Control and Estimation*2 is capable of high-speed processing and can collectively control large-scale applications across processes. Using this suite as its operating platform, Dynamic Real Time Optimizer achieves multi-unit optimization and control. Also, as it makes use of KBC’s simulation technologies, the Dynamic Real Time Optimizer software can obtain optimal values with high accuracy even with reaction processes that demonstrate non-linear characteristics.

2. Integrated solution with improved maintainability

The performance of advanced control and optimization systems tends to degrade over time due to changes in operating conditions, catalyst activity changes, and the aging of facilities. Dynamic Real Time Optimizer is designed to maintain advanced control performance even as a plant changes, by using an online Petro-SIM model. The structure of this solution makes it easy to maintain advanced control and optimization systems, thus enabling operators to achieve optimal performance with nearly no change in maintenance workload.

*1 A method for determining the appropriate approach within a given range of rules, using mathematical models and computers
*2 A software suite with the following functionality:
- Multivariable model predictive control (the control of multiple variables based on predictions made using models of the dynamic characteristics of plant responses)
- Soft sensing for estimating quality in real time based on temperature, flow rate, pressure, and other process values
- Customization of calculations

Major Applications

Advanced control of continuous plant processes in the oil, petrochemical, chemical, gas, and other industries

For more information

https://www.yokogawa.com/solutions/solutions/oprex/oprex-transformation/oprex-asset-operations-and-optimization/dynamic-real-time-optimizer-rt-op

About OpreX

OpreX is the comprehensive brand for Yokogawa’s industrial automation (IA) and control business. The OpreX name stands for excellence in the technologies and solutions that Yokogawa cultivates through the co-creation of value with its customers, and encompasses the entire range of Yokogawa’s IA products, services, and solutions. This brand comprises the following five categories: OpreX Transformation, OpreX Control, OpreX Measurement, OpreX Execution, and OpreX Lifecycle. Platform for Advanced Control and Estimation, an OpreX Asset Operations and Optimization family solution in the OpreX Transformation category, delivers operational excellence throughout an enterprise’s activities, from production through to supply chain optimization and risk and business management.

With this brand, Yokogawa will deliver integrated solutions that address specific needs and support its customers in their efforts to transform and grow their businesses.

About Yokogawa

Founded in 1915, Yokogawa engages in broad-ranging activities in the areas of measurement, control, and information. The industrial automation business provides vital products, services, and solutions to a diverse range of process industries including oil, chemicals, natural gas, power, iron and steel, and pulp and paper. With the life innovation business, the company aims to radically improve productivity across the pharmaceutical and food industry value chains. The test & measurement, aviation, and other businesses continue to provide essential instruments and equipment with industry-leading precision and reliability. Yokogawa co-innovates with its customers through a global network of 113 companies spanning 60 countries, generating US$3.6 billion in sales in FY2018. For more information, please visit www.yokogawa.com .

The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release

Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu

HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release

Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release

- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o

SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release

Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye